RT Journal Article
SR Electronic
T1 Ticagrelor responsive platelet genes are associated with platelet function and bleeding
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.18.22270280
DO 10.1101/2022.03.18.22270280
A1 Myers, Rachel A
A1 Ortel, Thomas L
A1 Waldrop, Alexander
A1 Dave, Sandeep
A1 Ginsburg, Geoffrey S
A1 Voora, Deepak
YR 2022
UL http://medrxiv.org/content/early/2022/03/18/2022.03.18.22270280.abstract
AB Importance Ticagrelor inhibits platelet function, prevents myocardial infarction, and causes bleeding. A comprehensive analysis of the on- and off-target platelet effects of ticagrelor that underlie its clinical effects is lacking.Objective To test the hypothesis that platelet transcripts that change in response to ticagrelor exposure are associated with platelet function or bleeding.Design A discovery cohort of healthy volunteers were sequentially exposed to aspirin, aspirin washout, and ticagrelor. Messenger RNA sequencing (mRNAseq) of purified platelets was performed pre/post each exposure. We defined the ticagrelor exposure signature (TES) as the ratio of mean expression of up-vs. down-regulated genes by ticagrelor that were prioritized based on lasso regression, weighted gene co-expression networks, and isoform level analyses. A separate healthy cohort was recruited to validate ticagrelor’s effects on TES genes measured using Nanostring. Platelet function was measured at baseline and in response to ticagrelor exposure in all participants. Self-reported bleeding was systematically queried during periods of ticagrelor exposure.Setting An early phase, academic, clinical research unit.Participants Self-reported, healthy volunteers age > 30 and < 75, non-smoking, taking no daily prescribed medications.Exposures Ticagrelor (90 mg twice daily) and aspirin (81 mg/day and 325 mg/day) each for 4 weeks.Main outcomes and measures Expression levels of platelet messenger RNA, platelet count, mean platelet volume, and 9 different measures of ex vivo platelet function (aggregated into a previously described platelet function score), and self-reported bleeding at baseline and after each exposure.Results In the discovery cohort (n = 58, mean age 43, 39 female) platelet mRNAseq identified (FDR < 5%) 1820 up- and 1589 down-regulated genes associated with ticagrelor exposure. We prioritized 84 of these transcripts to calculate a TES score, which was increased by ticagrelor and unaffected by either dose of aspirin. In an independent cohort (n = 49, mean age 44, 24 female) we validated that ticagrelor exposure (beta = 0.48, SE = 0.08, p < 0.0001) increases TES scores. In combined analyses of discovery and validation cohorts, when TES levels were calculated using baseline platelet RNA, higher TES levels were associated with lower levels of baseline platelet function (meta-analysis beta = -0.60, standard error [SE] 0.29, P = 0.04) and self-reported bleeding during ticagrelor exposure (meta-analysis beta = 0.28, standard error [SE] = 0.14, P = 0.04). In contrast, we found no associations between bleeding with baseline platelet count, platelet volume, or platelet function.Conclusions and Relevance Ticagrelor exposure reproducibly and specifically changes a set of platelet transcripts, the baseline levels of which are a biomarker for platelet function and bleeding tendency on ticagrelor.Question What are the global effects of ticagrelor exposure on platelets beyond platelet inhibition?Findings In an experimental human study of different antiplatelet therapies, we comprehensively characterized the effects of ticagrelor on platelet messenger RNA (mRNA). We found that 4 weeks of 90mg twice daily ticagrelor therapy specifically and reproducibly changes the levels of selected platelet mRNA. At baseline, volunteers with levels of platelet gene expression that mimic ticagrelor exposure had lower levels of platelet function and when exposed to ticagrelor a greater tendency for minor bleeding.Meaning By using ticagrelor exposure as a molecular probe, we identified a platelet RNA biomarker that may identify patients at higher risk for ticagrelor-associated bleeding.Competing Interest StatementAztraZeneca (Research Grant)Clinical TrialNCT05278637Funding StatementThis study was supported by institutional funds from the Duke Institute for Genome Sciences & Policy; National Institutes of Health (NIH) T32 training grant 5T32HL007101; NIH/National Center for Research Resources grant 5UL1RR024128; National Institutes of General Medical Sciences grant 5RC1GM091083; National Heart Lung Blood Institute grant 5R01HL118049; Centers for Disease Control and Prevention grant 5U01DD000014; and a grant from the David H. Murdock Research Institute; and a research grant from AztraZenecaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Duke University Institutional Review Board approved all study protocols.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGene Expression Omnibus (GSE158765)